Related Experiment Video

Updated: Jul 8, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Mammalian target of rapamycin as a therapeutic target in oncology

Robert T Abraham1, Christina H Eng

  • 1Oncology Discovery Research, Wyeth, 401 N. Middletown Road, Pearl River, NY 10965, USA. abrahar@wyeth.com

Expert Opinion on Therapeutic Targets
|January 23, 2008
PubMed
Abstract

Insights

Mammalian target of rapamycin (mTOR) inhibitors are crucial for cancer therapy. Understanding their antitumor mechanisms will lead to better combination treatments and new drug development for human cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The mammalian target of rapamycin (mTOR) pathway is a key regulator of cell growth and metabolism.
  • mTOR is a validated therapeutic target in various cancers.
  • mTOR inhibitors modulate tumor cell responses to growth signals and stress.

Purpose of the Study:

  • To review the mTOR signaling pathway.
  • To discuss the rationale for using mTOR inhibitors in oncology.
  • To explore the clinical applications of rapamycin analogs and other mTOR inhibitors.

Main Methods:

  • Literature review of recent publications.
  • Analysis of early clinical experience with mTOR inhibitors.
  • Inclusion of conjectural viewpoints on mTOR inhibition.

Main Results:

  • mTOR inhibitors impact tumor cell signaling and stress responses.
  • Early clinical data informs the use of mTOR inhibitors in cancer patients.
  • Understanding mechanisms is key to overcoming resistance.

Conclusions:

  • A deep understanding of antitumor mechanisms is essential for developing effective combination therapies.
  • Overcoming tumor resistance to mTOR inhibitors requires further research.
  • Second-generation mTOR inhibitors may offer enhanced therapeutic activity in human cancers.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...